DrugPatentWatch Database Preview

Details for Patent: 9,226,892

Which drugs does patent 9,226,892 protect, and when does it expire?

Patent 9,226,892 protects ASPIRIN and is included in one NDA.

This patent has eleven patent family members in nine countries.

Summary for Patent: 9,226,892

Title:	pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Abstract:	Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia.
Inventor(s):	Marathi; Upendra K. (Houston, TX), Childress; Susann Edler (Houston, TX), Gammill; Shaun L. (Houston, TX), Strozier; Robert W. (Houston, TX)
Assignee:	PLX PHARMA INC. (Houston, TX)
Application Number:	13/791,189
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 9,226,892

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Plx Pharma	ASPIRIN	aspirin	CAPSULE;ORAL	203697-001	Jan 14, 2013		OTC	Yes	Yes	➤ Sign Up	➤ Sign Up				TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE	➤ Sign Up
Plx Pharma	ASPIRIN	aspirin	CAPSULE;ORAL	203697-001	Jan 14, 2013		OTC	Yes	Yes	➤ Sign Up	➤ Sign Up				TEMPORARY RELIEF OF MINOR ACHES AND PAINS	➤ Sign Up
Plx Pharma	ASPIRIN	aspirin	CAPSULE;ORAL	203697-001	Jan 14, 2013		OTC	Yes	Yes	➤ Sign Up	➤ Sign Up				TEMPORARY REDUCTION OF FEVER	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 9,226,892

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
9,216,150	pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same	➤ Sign Up
9,730,884	pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 9,226,892

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012315545	➤ Sign Up
Canada	2850187	➤ Sign Up
China	103957888	➤ Sign Up
European Patent Office	2760433	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 9,226,892

For more information try a trial or see the plans and pricing